Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC).

Spachmann PJ, Azzolina V, Weber F, Evert M, Eckstein M, Denzinger S, Burger M, Otto W, Breyer J.

Pathol Oncol Res. 2019 Sep 10. doi: 10.1007/s12253-019-00745-7. [Epub ahead of print]

PMID:
31506803
2.

Hospital quality indicators: a systematic review.

Breyer JZ, Giacomazzi J, Kuhmmer R, Lima KM, Hammes LS, Ribeiro RA, Kops NL, Falavigna M, Wendland EM.

Int J Health Care Qual Assur. 2019 Mar 11;32(2):474-487. doi: 10.1108/IJHCQA-04-2018-0091.

PMID:
31017060
3.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
4.

Impact of E-Cadherin and β-Catenin as Prognostic Factor in Renal Cell Carcinoma with Tumor Thrombus of the Vena Cava.

Spachmann PJ, Breyer J, Kalogirou C, Lausenmeyer EM, Weber F, Prohaska S, Denzinger S, Burger M, Kübler H, Otto W, Vergho D.

Urol Int. 2019;102(4):413-420. doi: 10.1159/000497279. Epub 2019 Mar 7.

PMID:
30844790
5.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

6.

Andrea Farkas Patenaude (1946-2018).

Kupst MJ, Breyer J.

Am Psychol. 2019 Feb-Mar;74(2):256. doi: 10.1037/amp0000345.

PMID:
30762393
7.

Erratum to 'Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy' [Urologic Oncology: Seminars and Original Investigations 36/12 (2018) 505-534].

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2019 Mar;37(3):227. doi: 10.1016/j.urolonc.2018.12.019. Epub 2018 Dec 27. No abstract available.

PMID:
30595464
8.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
9.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

PMID:
30483954
10.

Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13. Erratum in: Urol Oncol. 2019 Mar;37(3):227.

PMID:
30446441
11.

Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.

Lausenmeyer EM, Braun K, Breyer J, Gierth M, Denzinger S, Burger M, Voelker HU, Otto W.

Urol Int. 2019;102(1):77-82. doi: 10.1159/000493577. Epub 2018 Nov 1.

PMID:
30384365
12.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

13.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

14.

[Role of p16(INK4A) in detection of human papillomavirus DNA and stratification of cancer-specific mortality on the basis of long term follow-up data of 34 patients with invasive penile cancer].

Bründl J, Neppl C, Hommer T, Otto W, Breyer J, Brookman-May S, Weber F, Burger M, May M, Eichelberg C.

Aktuelle Urol. 2019 Sep;50(5):491-501. doi: 10.1055/a-0664-0316. Epub 2018 Sep 18. German.

PMID:
30227445
15.

Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue.

Bründl J, Wallinger S, Breyer J, Weber F, Evert M, Georgopoulos NT, Rosenhammer B, Burger M, Otto W, Rubenwolf P.

BMC Urol. 2018 Sep 3;18(1):75. doi: 10.1186/s12894-018-0391-y.

16.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

PMID:
30120861
17.

[Imaging in individualized uro-oncology].

Bründl J, Breyer J, Burger M.

Urologe A. 2018 Sep;57(9):1048-1057. doi: 10.1007/s00120-018-0729-9. Review. German.

PMID:
30054677
18.

FOXM1 predicts disease progression in non-muscle invasive bladder cancer.

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

19.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
20.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

21.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
22.

Accordance of Online Health Information on Prostate Cancer with the European Association of Urology Guidelines.

Bruendl J, Rothbauer C, Ludwig B, Dotzler B, Wolff C, Reimann S, Borgmann H, Burger M, Breyer J.

Urol Int. 2018;100(3):288-293. doi: 10.1159/000487146. Epub 2018 Mar 7.

PMID:
29514140
23.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

24.

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A.

Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22.

25.

Assessment of potential risk factors for breast cancer in a population in Southern Brazil.

Breyer JZ, Wendland EM, Kops NL, Caleffi M, Hammes LS.

Breast Cancer Res Treat. 2018 May;169(1):125-131. doi: 10.1007/s10549-017-4655-0. Epub 2018 Jan 17.

PMID:
29344741
26.

Improving outcome and prognosis prediction in non-muscle invasive bladder cancer using a gene expression score.

Breyer J.

Transl Androl Urol. 2017 Oct;6(5):991-993. doi: 10.21037/tau.2017.09.06. No abstract available.

27.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A.

Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

PMID:
29150702
28.

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A.

Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

29.

Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer.

Breyer J, Shalekenov S, Aziz A, van Rhijn BWG, Bründl J, Lausenmeyer E, Schäfer J, Denzinger S, Giedl C, Burger M, Hartmann A, Evert M, Otto W.

Bladder Cancer. 2017 Jul 27;3(3):173-180. doi: 10.3233/BLC-170103.

30.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

31.

[Clinical and pathological prognostic factors for the long-term survival of patients with pT1 renal cell carcinoma].

Breyer J, Otto W, Lausenmeyer EM, Denzinger S, Schwientek AK, Ochs L, Mayr R, Gierth M, Bründl J, Burger M, Evert M, Fritsche HM, Eichelberg C.

Aktuelle Urol. 2017 May;48(3):230-237. doi: 10.1055/s-0043-101725. Epub 2017 Apr 19. German.

PMID:
28423432
32.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

33.

Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?

Breyer J, Otto W, Burger M, Hartmann A, Rubenwolf PC.

Bladder Cancer. 2017 Jan 27;3(1):31-34. doi: 10.3233/BLC-160082.

34.

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.

PMID:
28074276
35.

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Otto W, Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A.

Int Urol Nephrol. 2017 Mar;49(3):431-437. doi: 10.1007/s11255-016-1491-9. Epub 2016 Dec 29.

PMID:
28035618
36.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
37.

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P.

Anticancer Res. 2016 Oct;36(10):5205-5213.

PMID:
27798881
38.

Immunotherapy in urothelial carcinoma: fade or future standard?

Breyer J, Burger M, Otto W.

Transl Androl Urol. 2016 Oct;5(5):662-667. Review.

39.

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W.

Virchows Arch. 2016 Nov;469(5):547-552. Epub 2016 Aug 11.

PMID:
27514658
40.

Downregulation of Checkpoint Protein Kinase 2 in the Urothelium of Healthy Male Tobacco Smokers.

Breyer J, Denzinger S, Hartmann A, Otto W.

Urol Int. 2016;97(4):480-481. Epub 2016 Jun 2.

PMID:
27251560
41.

Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.

Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C, Otto W.

World J Urol. 2016 May;34(5):709-16. doi: 10.1007/s00345-015-1690-5. Epub 2015 Sep 22.

PMID:
26394624
42.

Prostate Cancer on the Web-Expedient Tool for Patients' Decision-Making?

Borgmann H, Wölm JH, Vallo S, Mager R, Huber J, Breyer J, Salem J, Loeb S, Haferkamp A, Tsaur I.

J Cancer Educ. 2017 Mar;32(1):135-140. doi: 10.1007/s13187-015-0891-3.

PMID:
26234650
43.

[Anamnesis, Pathological Assessment, Therapeutic Features and Course of Disease: Retrospective Study on Clinical-Based Factors for Prediction of Cancer-Specific Survival of 378 Patients with Stage pT1 Urothelial Bladder Carcinoma].

Breyer J, Otto W, Hartmann A, Bumes B, Bründl J, Gierth M, Bertz S, Denzinger S, Burger M, Lausenmeyer EM.

Aktuelle Urol. 2015 May;46(3):221-6. doi: 10.1055/s-0035-1549905. Epub 2015 Jun 12. German.

PMID:
26077306
44.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

45.

Outcome of patients with pathological tumor stage T3 urothelial carcinoma of the bladder following radical cystectomy in a single-center series with 116 patients.

Breyer J, Denzinger S, Otto W, Bründl J, Gierth M, Fritsche HM, Rößler W, Wieland WF, Giedl C, Hofstädter F, Rubenwolf P, Burger M, Aziz A.

Urol Int. 2014;93(3):311-9. doi: 10.1159/000360483. Epub 2014 Sep 4.

PMID:
25196313
46.

Constraints on cosmic strings from the LIGO-Virgo gravitational-wave detectors.

Aasi J, Abadie J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Accadia T, Acernese F, Adams C, Adams T, Adhikari RX, Affeldt C, Agathos M, Aggarwal N, Aguiar OD, Ajith P, Allen B, Allocca A, Amador Ceron E, Amariutei D, Anderson RA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux C, Areeda J, Ast S, Aston SM, Astone P, Aufmuth P, Aulbert C, Austin L, Aylott BE, Babak S, Baker PT, Ballardin G, Ballmer SW, Barayoga JC, Barker D, Barnum SH, Barone F, Barr B, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Basti A, Batch J, Bauchrowitz J, Bauer TS, Bebronne M, Behnke B, Bejger M, Beker MG, Bell AS, Bell C, Belopolski I, Bergmann G, Berliner JM, Bersanetti D, Bertolini A, Bessis D, Betzwieser J, Beyersdorf PT, Bhadbhade T, Bilenko IA, Billingsley G, Birch J, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Blom M, Bock O, Bodiya TP, Boer M, Bogan C, Bond C, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Boschi V, Bose S, Bosi L, Bowers J, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brannen CA, Brau JE, Breyer J, Briant T, Bridges DO, Brillet A, Brinkmann M, Brisson V, Britzger M, Brooks AF, Brown DA, Brown DD, Brückner F, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Calderón Bustillo J, Calloni E, Camp JB, Campsie P, Cannon KC, Canuel B, Cao J, Capano CD, Carbognani F, Carbone L, Caride S, Castiglia A, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda C, Cesarini E, Chakraborty R, Chalermsongsak T, Chao S, Charlton P, Chassande-Mottin E, Chen X, Chen Y, Chincarini A, Chiummo A, Cho HS, Chow J, Christensen N, Chu Q, Chua SS, Chung S, Ciani G, Clara F, Clark DE, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Colombini M, Constancio M Jr, Conte A, Conte R, Cook D, Corbitt TR, Cordier M, Cornish N, Corsi A, Costa CA, Coughlin MW, Coulon JP, Countryman S, Couvares P, Coward DM, Cowart M, Coyne DC, Craig K, Creighton JD, Creighton TD, Crowder SG, Cumming A, Cunningham L, Cuoco E, Dahl K, Dal Canton T, Damjanic M, Danilishin SL, D'Antonio S, Danzmann K, Dattilo V, Daudert B, Daveloza H, Davier M, Davies GS, Daw EJ, Day R, Dayanga T, De Rosa R, Debreczeni G, Degallaix J, Del Pozzo W, Deleeuw E, Deléglise S, Denker T, Dent T, Dereli H, Dergachev V, DeRosa R, DeSalvo R, Dhurandhar S, Di Fiore L, Di Lieto A, Di Palma I, Di Virgilio A, Díaz M, Dietz A, Dmitry K, Donovan F, Dooley KL, Doravari S, Drago M, Drever RW, Driggers JC, Du Z, Dumas JC, Dwyer S, Eberle T, Edwards M, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Endrőczi G, Essick R, Etzel T, Evans K, Evans M, Evans T, Factourovich M, Fafone V, Fairhurst S, Fang Q, Farinon S, Farr B, Farr W, Favata M, Fazi D, Fehrmann H, Feldbaum D, Ferrante I, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fisher R, Flaminio R, Foley E, Foley S, Forsi E, Fotopoulos N, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei M, Frei Z, Freise A, Frey R, Fricke TT, Fritschel P, Frolov VV, Fujimoto MK, Fulda P, Fyffe M, Gair J, Gammaitoni L, Garcia J, Garufi F, Gehrels N, Gemme G, Genin E, Gennai A, Gergely L, Ghosh S, Giaime JA, Giampanis S, Giardina KD, Giazotto A, Gil-Casanova S, Gill C, Gleason J, Goetz E, Goetz R, Gondan L, González G, Gordon N, Gorodetsky ML, Gossan S, Goßler S, Gouaty R, Graef C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJ, Gretarsson AM, Griffo C, Groot P, Grote H, Grover K, Grunewald S, Guidi GM, Guido C, Gushwa KE, Gustafson EK, Gustafson R, Hall B, Hall E, Hammer D, Hammond G, Hanke M, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Hartman MT, Haughian K, Hayama K, Heefner J, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Heptonstall AW, Heurs M, Hild S, Hoak D, Hodge KA, Holt K, Holtrop M, Hong T, Hooper S, Horrom T, Hosken DJ, Hough J, Howell EJ, Hu Y, Hua Z, Huang V, Huerta EA, Hughey B, Husa S, Huttner SH, Huynh M, Huynh-Dinh T, Iafrate J, Ingram DR, Inta R, Isogai T, Ivanov A, Iyer BR, Izumi K, Jacobson M, James E, Jang H, Jang YJ, Jaranowski P, Jiménez-Forteza F, Johnson WW, Jones D, Jones DI, Jones R, Jonker RJ, Ju L, K H, Kalmus P, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Kasprzack M, Kasturi R, Katsavounidis E, Katzman W, Kaufer H, Kaufman K, Kawabe K, Kawamura S, Kawazoe F, Kéfélian F, Keitel D, Kelley DB, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim BK, Kim C, Kim K, Kim N, Kim W, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kline J, Koehlenbeck S, Kokeyama K, Kondrashov V, Koranda S, Korth WZ, Kowalska I, Kozak D, Kremin A, Kringel V, Królak A, Kucharczyk C, Kudla S, Kuehn G, Kumar A, Kumar P, Kumar R, Kurdyumov R, Kwee P, Landry M, Lantz B, Larson S, Lasky PD, Lawrie C, Lazzarini A, Le Roux A, Leaci P, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee J, Lee J, Leonardi M, Leong JR, Leroy N, Letendre N, Levine B, Lewis JB, Lhuillier V, Li TG, Lin AC, Littenberg TB, Litvine V, Liu F, Liu H, Liu Y, Liu Z, Lloyd D, Lockerbie NA, Lockett V, Lodhia D, Loew K, Logue J, Lombardi AL, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Luan J, Lubinski MJ, Lück H, Lundgren AP, Macarthur J, Macdonald E, Machenschalk B, MacInnis M, Macleod DM, Magana-Sandoval F, Mageswaran M, Mailand K, Majorana E, Maksimovic I, Malvezzi V, Man N, Manca GM, Mandel I, Mandic V, Mangano V, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan A, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Martinelli L, Martynov D, Marx JN, Mason K, Masserot A, Massinger TJ, Matichard F, Matone L, Matzner RA, Mavalvala N, May G, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIver J, Meacher D, Meadors GD, Mehmet M, Meidam J, Meier T, Melatos A, Mendell G, Mercer RA, Meshkov S, Messenger C, Meyer MS, Miao H, Michel C, Mikhailov EE, Milano L, Miller J, Minenkov Y, Mingarelli CM, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Mohan M, Mohapatra SR, Mokler F, Moraru D, Moreno G, Morgado N, Mori T, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Mukherjee S, Mullavey A, Munch J, Murphy D, Murray PG, Mytidis A, Nagy MF, Nanda Kumar D, Nardecchia I, Nash T, Naticchioni L, Nayak R, Necula V, Nelemans G, Neri I, Neri M, Newton G, Nguyen T, Nishida E, Nishizawa A, Nitz A, Nocera F, Nolting D, Normandin ME, Nuttall LK, Ochsner E, O'Dell J, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oppermann P, O'Reilly B, Ortega Larcher W, O'Shaughnessy R, Osthelder C, Ott CD, Ottaway DJ, Ottens RS, Ou J, Overmier H, Owen BJ, Padilla C, Pai A, Palomba C, Pan Y, Pankow C, Paoletti F, Paoletti R, Papa MA, Paris H, Pasqualetti A, Passaquieti R, Passuello D, Pedraza M, Peiris P, Penn S, Perreca A, Phelps M, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pinard L, Pindor B, Pinto IM, Pitkin M, Poeld J, Poggiani R, Poole V, Poux C, Predoi V, Prestegard T, Price LR, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Quetschke V, Quintero E, Quitzow-James R, Raab FJ, Rabeling DS, Rácz I, Radkins H, Raffai P, Raja S, Rajalakshmi G, Rakhmanov M, Ramet C, Rapagnani P, Raymond V, Re V, Reed CM, Reed T, Regimbau T, Reid S, Reitze DH, Ricci F, Riesen R, Riles K, Robertson NA, Robinet F, Rocchi A, Roddy S, Rodriguez C, Rodruck M, Roever C, Rolland L, Rollins JG, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Salemi F, Sammut L, Sandberg V, Sanders J, Sannibale V, Santiago-Prieto I, Saracco E, Sassolas B, Sathyaprakash BS, Saulson PR, Savage R, Schilling R, Schnabel R, Schofield RM, Schreiber E, Schuette D, Schulz B, Schutz BF, Schwinberg P, Scott J, Scott SM, Seifert F, Sellers D, Sengupta AS, Sentenac D, Sergeev A, Shaddock D, Shah S, Shahriar MS, Shaltev M, Shapiro B, Shawhan P, Shoemaker DH, Sidery TL, Siellez K, Siemens X, Sigg D, Simakov D, Singer A, Singer L, Sintes AM, Skelton GR, Slagmolen BJ, Slutsky J, Smith JR, Smith MR, Smith RJ, Smith-Lefebvre ND, Soden K, Son EJ, Sorazu B, Souradeep T, Sperandio L, Staley A, Steinert E, Steinlechner J, Steinlechner S, Steplewski S, Stevens D, Stochino A, Stone R, Strain KA, Straniero N, Strigin S, Stroeer AS, Sturani R, Stuver AL, Summerscales TZ, Susmithan S, Sutton PJ, Swinkels B, Szeifert G, Tacca M, Talukder D, Tang L, Tanner DB, Tarabrin SP, Taylor R, ter Braack AP, Thirugnanasambandam MP, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari V, Tokmakov KV, Tomlinson C, Toncelli A, Tonelli M, Torre O, Torres CV, Torrie CI, Travasso F, Traylor G, Tse M, Ugolini D, Unnikrishnan CS, Vahlbruch H, Vajente G, Vallisneri M, van den Brand JF, Van Den Broeck C, van der Putten S, van der Sluys MV, van Heijningen J, van Veggel AA, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Verma S, Vetrano F, Viceré A, Vincent-Finley R, Vinet JY, Vitale S, Vlcek B, Vo T, Vocca H, Vorvick C, Vousden WD, Vrinceanu D, Vyachanin SP, Wade A, Wade L, Wade M, Waldman SJ, Walker M, Wallace L, Wan Y, Wang J, Wang M, Wang X, Wanner A, Ward RL, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Wessels P, West M, Westphal T, Wette K, Whelan JT, Whitcomb SE, White DJ, Whiting BF, Wibowo S, Wiesner K, Wilkinson C, Williams L, Williams R, Williams T, Willis JL, Willke B, Wimmer M, Winkelmann L, Winkler W, Wipf CC, Wittel H, Woan G, Worden J, Yablon J, Yakushin I, Yamamoto H, Yancey CC, Yang H, Yeaton-Massey D, Yoshida S, Yum H, Yvert M, Zadrożny A, Zanolin M, Zendri JP, Zhang F, Zhang L, Zhao C, Zhu H, Zhu XJ, Zotov N, Zucker ME, Zweizig J; LIGO Scientific Collaboration; Virgo Collaboration.

Phys Rev Lett. 2014 Apr 4;112(13):131101. Epub 2014 Apr 4.

47.

A longitudinal study of childhood ADHD and substance dependence disorders in early adulthood.

Breyer JL, Lee S, Winters KC, August GJ, Realmuto GM.

Psychol Addict Behav. 2014 Mar;28(1):238-46. doi: 10.1037/a0035664.

48.

An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility.

Breyer JP, Dorset DC, Clark TA, Bradley KM, Wahlfors TA, McReynolds KM, Maynard WH, Chang SS, Cookson MS, Smith JA, Schleutker J, Dupont WD, Smith JR.

Am J Hum Genet. 2014 Mar 6;94(3):395-404. doi: 10.1016/j.ajhg.2014.01.019. Epub 2014 Feb 27.

49.

Metacarpophalangeal and interphalangeal joint arthrodesis: a comparative study between tension band and compression screw fixation.

Breyer JM, Vergara P, Parra L, Sotelo P, Bifani A, Andrade F.

J Hand Surg Eur Vol. 2015 May;40(4):374-8. doi: 10.1177/1753193413514362. Epub 2014 Jan 15.

PMID:
24436361
50.

HIF-1α activation results in actin cytoskeleton reorganization and modulation of Rac-1 signaling in endothelial cells.

Weidemann A, Breyer J, Rehm M, Eckardt KU, Daniel C, Cicha I, Giehl K, Goppelt-Struebe M.

Cell Commun Signal. 2013 Oct 21;11:80. doi: 10.1186/1478-811X-11-80.

Supplemental Content

Loading ...
Support Center